By Fineline Cube 
UK pharmaceutical leader AstraZeneca (AZ, NASDAQ: AZN) has expanded its collaboration with US-based Tempus AI, Inc. (NASDAQ: TEM) to include Pathos AI, Inc. in a multi-year initiative. The partnership aims to develop an oncology-focused multimodal foundation model that integrates biological and clinical data to identify novel drug targets and accelerate therapeutic development.
Collaboration Details
This expanded partnership builds on the existing alliance between AstraZeneca and Tempus established in 2021. Tempus will contribute de-identified oncology datasets to train the foundational model. Once developed, the model will be accessible to all three parties to enhance their respective patient care and research initiatives. Financial terms include USD 200 million in combined data licensing and model development fees to be paid to Tempus.-Fineline Info & Tech